Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 176 participants.

Also called NCT02532218

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 176 participants (planned count) (from the registry)
Sponsor
Arisaph Pharmaceuticals Inc (from the registry)
Registry
  • NCT NCT02532218
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02532218. Randomized; quadruple masking; primary purpose treatment. Start 2015-08 (registry gives no type); primary completion 2016-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia
Acronym
REASCEND
Condition
Hyperlipidemia
Intervention (Drug)
ARI-3037MO
Lead sponsor
Arisaph Pharmaceuticals Inc (class: industry)

Record details

Record id
cardio:ct-nct02532218
Content hash
0f58cd444749accbc8c80665ee5bc14ced2f09459aa569ac37980f6b382871c8